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Abstract

Multiple sclerosis (MS) is associated with breakdown of the myelin sheath that coats neurons in the central
nervous system. The cause of MS is not known, although the pathogenesis involves destruction of myelin by
the immune system. It was the aim of this study to examine the abundant myelin protein, myelin basic protein
(MBP), to determine if there are sites of modification that may be characteristic for MS. MBP from the
cerebellum was examined from controls and MS patients across the age range using mass spectrometry and
amino acid analysis. Amino acid racemization data indicated that myelin basic protein is long-lived and
proteomic analysis of MBP showed it to be highly modified. A common modification of MBP was
racemization of Asp and this was significantly greater in MS patients. In long-lived proteins, L-Asp and L-Asn
can racemize to three other isomers, D-isoAsp, L-isoAsp and D-Asp and this is significant because isoAsp
formation in peptides renders them immunogenic.Proteomic analysis revealed widespread modifications of
MBP with two surface regions that are altered in MS. In particular, isoAsp was significantly elevated at these
sites in MS patients. The generation of isoAsp could be responsible for eliciting an immune response to
modified MBP and therefore be implicated in the etiology of MS.
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Isoaspartic acid is present at specific sites
in myelin basic protein from multiple
sclerosis patients: could this represent a
trigger for disease onset?
Michael G. Friedrich1,2*, Sarah E. Hancock1,2, Mark J. Raftery3 and Roger J. W. Truscott1*

Abstract
Multiple sclerosis (MS) is associated with breakdown of the myelin sheath that coats neurons in the central nervous
system. The cause of MS is not known, although the pathogenesis involves destruction of myelin by the immune
system. It was the aim of this study to examine the abundant myelin protein, myelin basic protein (MBP), to
determine if there are sites of modification that may be characteristic for MS. MBP from the cerebellum was
examined from controls and MS patients across the age range using mass spectrometry and amino acid analysis.
Amino acid racemization data indicated that myelin basic protein is long-lived and proteomic analysis of MBP
showed it to be highly modified. A common modification of MBP was racemization of Asp and this was
significantly greater in MS patients. In long-lived proteins, L-Asp and L-Asn can racemize to three other
isomers, D-isoAsp, L-isoAsp and D-Asp and this is significant because isoAsp formation in peptides renders
them immunogenic.
Proteomic analysis revealed widespread modifications of MBP with two surface regions that are altered in MS.
In particular, isoAsp was significantly elevated at these sites in MS patients. The generation of isoAsp could
be responsible for eliciting an immune response to modified MBP and therefore be implicated in the etiology
of MS.

Introduction
MS has long been thought to be an autoimmune disease.
Injection of brain homogenates into animals results in
demyelination resembling that seen in MS [33] and a
body of data, including the presence of antibodies to
myelin components in MS patients, supports a role
for an autoimmune response in the genesis of human
MS [32, 42].
MBP accounts for 35 % of myelin protein and is
intrinsically unstructured [16] Recently, MBP and other
proteins in myelin were shown to be long-lived [35].
Over time, long-lived proteins degrade and this timedependent deterioration has been well studied in the
lens, a tissue with no protein turnover. In lens proteins,
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age-related post-translational modifications (PTMs) were
localized to unstructured regions [19] and racemization,
which involves conversion of L- to D-amino acid residues, was found to be the most abundant type of
PTM [39]. D-amino acids at some sites were present
at levels that exceeded the amount of the precursor
L-amino acid [21].
In humans, major proteins from cataract lenses are
characterized by specific racemization sites that differ
from those in comparable age-matched normal lenses
[18, 20, 21]. This finding implies that pathways of
protein degradation in the body may possibly determine
disease outcome. In long-lived proteins, Asp and Asn
residues are particularly sensitive to racemization,
undergoing a spontaneous cyclisation reaction that leads
to the formation of L-Asp, D-Asp, L-isoAsp and DisoAsp (see Fig. 2). isoAsp residues are typically present
in the highest amounts [13].
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Modifications on this scale inevitably have consequences for protein structure and can lead to a functional decline of the protein [34]. Recently it has been
shown that the formation of isoAsp can also lead to
altered immunogenicity of peptides/proteins, inducing
both T and B cell immunity [11]. Thus, like citrulline
formation from Arg residues, conversion of Asp/Asn to
isoAsp, can potentially induce an immune response to
self-antigens [10]. In the current study we examined the
hypothesis that since MBP is long-lived and unstructured it, like lens proteins, may also undergo significant
covalent alterations. For the reasons outlined above,
particular reference was paid to Asp/Asn racemizaton to
isoAsp. If specific PTMs such as these were found in the
MBP from MS patients, then they could play a role in
the etiology of MS by provoking an immune response to
the selectively modified myelin.

Materials and methods
Tissue samples

Cerebellum samples from control (n = 21) and MS patients (n = 8) were obtained from the New South Wales
Tissue Resource Centre at the University of Sydney with
approval from the University of Wollongong ethics committee (Ethics #11/267). MS patients were diagnosed as
follows: four with secondary progressive MS (ages 65,
68, 48, 60), two with relapsing remitting MS (ages 70
and 72) and two with primary progressive MS (ages 36
and 62). All MS samples displayed microscopically small
lesions with the exception of the 68 year-old patient.
Control and MS samples were analysed separately, blind
with respect to age and severity of MS. Further details
are provided in Additional file 1: Tables S1 and S2.
Homogenization of human brain tissue

Frozen cerebellum (Gyri of the posterior lobe) from controls (105 +/− 11 mg) and MS patients (115 +/− 13 mg)
was pulverized then homogenized as detailed in Norris
et. al. [30] After homogenization, each sample was
transferred to a 5 mL glass tube and centrifuged (1000 g,
10 min) at 4 °C. Myelin was enriched by use of a sucrose
gradient as described in Larocca and Norton [23].
Purification of MBP

Myelin basic protein was enriched with modifications to
the protocol of Chevalier and Allen [7]. Briefly, the
enriched myelin fraction was re-suspended in 50 mM
Tris buffer (pH 7.4) and centrifuged (21,000 g, 20 min).
The supernatant was discarded and the pellet reextracted. The pellet was re-suspended in 50 mM
acetic acid (1 mL) and centrifuged (21,000 g, 20 min)
and the pellet re-extracted with 50 mM acetic acid.
The acetic acid extracts were combined and freeze
dried. Greater than 90 % purity of MBP was confirmed
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by SDS-PAGE (Additional file 1: Figure S2). Since
PTMs, such as those associated with aging, can cause
major alterations to the properties of proteins, MBP
was not separated into isoforms (charge isomers) prior
to proteomic analyses [22].
Amino acid analysis

D-amino acid content of MBP samples was determined
by amino acid analysis as described [18]. Three separate
runs were carried out for each sample on an Agilent
1100 HPLC system.
Capillary LC mass spectrometry

Capillary LC mass spectrometry was undertaken as
described [21]. Briefly, MBP (~50 μg) was digested with
sequence grade trypsin (1 μg) (Promega) for 16 h at 37 °
C. Peptides were desalted and concentrated using a
Ziptip (0.6 μL, C18 resin; Millipore) and freeze dried.
The lyophilised peptides were re-suspended in formic
acid:heptafluorobutyric acid:water (0.1:0.05:98.85). Tandem mass spectra were acquired after LC using a Thermo
LTQ Orbitrap as described [21].
Data were searched against the Swiss-Prot database
with a range of PTMs using MASCOT (Matrix Science,
UK), with enzyme specificity set to trypsin. Peptide
tolerance: 1 ppm; fragment tolerance: 0.6 Da with 1
missed cleavage. The following PTMs were listed as
variable modifications: deamidation (N,Q,R), oxidation
(H,W,M), methylation (R) and phosphorylation (S,T).
Routinely greater than 80 % sequence coverage of MBP
was observed. To confirm assignments, tandem mass
spectrometric fragmentation of each peak was performed and synthetic peptides incorporating the particular modified amino acid (see below for list of
commercial standards) were run using the same
method to confirm identity by comparison of retention
time and MS/MS.
Data analysis

The doubly charged ions [FFGGDR m/z = 349.66, FFG
GD(Cit)GAPK m/z = 526.76, GVDAQGTLSK m/z =
488.25, YLATASTMDHAR m/z = 668.82, TAHYGSLP
QK m/z = 551.28 and TAHYGSLPEK m/z = 551.78] and
triply charged ions [TQDENPVVHFFK m/z = 487.57 and
HRDTGILDSIGR m/z = 447.24] for MBP-derived tryptic
peptides were utilised for relative quantification. Their
intensities from the extracted ion chromatogram (XIC)
were determined using Xcalibur software. Peak areas of
each peptide were calculated using a smoothing method
[Gaussian, 7 points]. The MS/MS spectrum of each peptide was matched to the XIC, ensuring that the peak
areas used corresponded to that of the matched peptide.
The percentage of modification was calculated by using:
[Modified/(Modified + Non- modified)] × 100.
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Peptide standards

FFGGDR (MBP tryptic peptide 44–49), FFGGDRGAPK
and FFGGD(Cit)GAPK (MBP tryptic peptide 44–53),
GVDAQGTLSK, (MBP tryptic peptide 143–152), HRD
TGILDSIGR (MBP tryptic peptide 32–43), YLATAST
MDHAR (MBP tryptic peptide 14–25), TAHYGSLPQK
(MBP tryptic peptide 66–75), TAHYGSLPEK (MBP
tryptic peptide 66–75) and TQDENPVVHFFK MBP
(tryptic peptide 80–91) were synthesized by GLS Biochem (Shanghai, China). FFGGDR, FFGGDRGAPK, FFG
GD(Cit)GAPK, HRDTGILDSIGR, YLATASTMDAR, TQ
DENPVVHFFK and GVDAQGTLSK were synthesized
with aspartic acid in four structural isomers, i.e., L-aspartic
acid, L-isoaspartic acid, D-aspartic acid, or D-isoaspartic
acid. TAHYGSLPQK was synthesized with L- and Dversions of Ser.
Statistical analysis

Statistical analysis was performed using SPSS Statistics
(version 19, IBM Corp. NY, USA) and R (version 3.1.1).
Comparison of controls and MS patients was made
using a Mann Whitney U test with a significance level of
p = 0.05. Changes to controls with age were analysed by
linear regression. Prior to performing linear regression,
normality of the dependent variable was assessed by
examining the histograms of the standardised residuals
and non-normal data were transformed where required.

Results
Adult human MBP is extensively racemized

Racemization involves the conversion of an L-amino
acid to a D-amino acid and is a defining feature of longlived proteins e.g. [13, 18]. It significantly affects protein
structure and can lead to the formation of epitopes that
the body recognizes as being foreign [8]. Initial experiments established the overall degree of racemization of
MBP using acid hydrolysis followed by separation of the
L- and D-forms of individual amino acids by HPLC [18].
All samples showed substantial racemization, even MBP
from a 22 year-old was found to contain a high percentage of D-amino acids (Fig. 1). Indeed the levels of
racemization of Asx (i.e. Asn + Asp) (Fig. 1a) were approximately 5 % by age 22 and thus are comparable to
those found in human lens proteins [18], which do not
to turn over and contain high levels of D-Asp by early
adulthood [18]. In lens proteins, there is a rapid agedependent increase in racemization up to age ~20, after
which levels increase much more slowly [9]. This suggests that human MBP is a life-long protein although
further testing would be required to confirm this.
Racemization data of MBP from MS patients revealed
statistically significant increases in the overall extent of
racemization of Asx, Glx and Ser compared to controls
(Fig. 1a, b, c). On the basis of the number of Asn/Asp
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residues present in MBP, on average, approximately one
Asp residue in every MBP polypeptide is racemized MS
patients. In order to pinpoint the exact sites of modification of MBP, samples were treated with trypsin and the
peptides characterized by capillary liquid chromatography tandem mass spectrometry (LC-MS).
MBP from MS patients differs from controls

To determine the exact sites of modification, MBP
was digested with trypsin, which cleaves only at arginine and lysine residues, and the peptide mixture
examined by LC–MS. LC enables the separation of
racemized forms of each peptide in MBP and tandem
MS/MS fragments each peptide giving its sequence
and sites of modification. Initial proteomic data
showed that the degree of PTM of all MBP samples,
both in terms of the number of sites modified, as well
as the extent of modification, was considerable. At
several sites in MBP there were significant differences
in the degree of PTM between controls and MS patients. Individual sites are discussed below with a
more comprehensive analysis of all detected PTMs
provided in Additional file 1.
Aspartic acid

L-Asp and L-Asn residues in long-lived proteins can
undergo age-related racemization via an intramolecular
condensation involving a succinimide [13]. Hydrolysis of
the succinimide produces four structural isomers: LAsp, D-Asp, L-isoAsp and D-isoAsp [13] (see Fig. 2).
The formation of D-Asp, D-isoAsp and L-isoAsp from
L-Asp34 in MBP (32HRDTGILDSIGR43) as a function of
age is illustrated in Fig. 3. For each of the abnormal Asp
isomers there was a significantly greater amount present
in MBP from MS patients. Of particular importance,
neither D-isoAsp or nor L-isoAsp was detected in the
control samples. It should be noted that this peptide
contains an internal Arg33 residue that trypsin would
normally cleave. We suspected on the basis of previous
data [27] that racemization of the adjacent Asp may be
responsible. This was tested with four homologous MBP
(32–43) peptides. D-Asp and L-isoAsp or D-isoAsp on
the C-terminal side of Arg inhibited digestion by tryspin,
whereas the L-Asp form was cleaved efficiently.
Glutamine

Deamidation of Gln is another age-related modification of proteins [19]. The deamidation of Gln147
(143GVDAEGTLSK152) as a function of age is shown
in Fig. 4. The extent of deamidation of Gln147 increased linearly with age in control MBP, although
the values did not exceed 6 %. By contrast, in every
case deamidation of Gln147 in MBP from MS patients was greater than 6 % (Fig. 4).
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Fig. 1 Racemization of a aspartic acid and asparagine (Asx),
b glutamine and glutamic acid (Glx) and c serine (Ser) in MBP
isolated from controls (●) and multiple sclerosis (MS) patients
suffering from SPMS (○) PPMS (◊) and RRMS (▽) as a function of age.
Levels of D-Asx (p <0.01, Mann Whitney U), D-Glx (p = 0.016, Mann
Whitney U) and D-Ser (p = 0.007, Mann Whitney U) were significantly
elevated in MS patients. Age zero corresponds to MBP purified from
goat cerebellum (▼) and was used as a control for artifactual racemization during hydrolysis. All data are the mean ± SEM of three separate
HPLC runs. Racemization in this, and subsequent figures, was expressed
 
D
as a % DþL
. Controls, n = 15; multiple sclerosis patients n = 8. In this
case, and Figs. 2, 3, 4, 5 statistical analysis was undertaken on combined
controls vs combined MS patients

Because many amino acid residues in adult MBP were
found by proteomic analysis to be modified, in some cases
more than one PTM was detected in a single tryptic
peptide. This is illustrated in MBP (143GVDAEGTLSK152),
where, along with deamidation of Gln, Asp145 was also
isomerized. D-isoAsp levels were found to be increased
significantly in MS patients compared to controls for the
Glu form of this peptide (Fig. 5). The L-isoAsp and D-Asp
versions of the Glu version were not significantly different
from the controls (data not shown).
Arginine

Deimination of Arg residues yields citrulline, an amino acid
that is not cleaved by trypsin and therefore this PTM leads
to missed cleavages during digestion [4]. Fifteen of the 19
Arg sites in MBP showed some degree of conversion to citrulline (Additional file 1: Table S3). Therefore, the relative
quantification method used in this study took missed cleavages into account when determining the degree of agerelated MBP modification (see Additional file 1: Figure S1).
Deimination of Arg increased at some sites in an agedependent manner. This is illustrated for Arg49
(44FFGGDRGAPK53) that appeared to be converted
linearly to citrulline (Fig. 6a). This peptide also displayed
other MS-specific modifications. In MS samples, deimination of Arg49 was accompanied by isomerisation of Asp48
(44FFGGD(Cit)GAPK53). In MS patients 11 ± 3 % of citrullinated peptides were also racemized at Asp 48. This
combination of racemization of Asp48 and deimination of Arg49 was found only in MBP from MS
patients (Fig. 6b). Elevated deimination of Arg 65 and
Arg 122 was also detected in MBP from MS patients
(Additional file 1: Figure S1).
Interaction between other sites of modification

As noted, a number of tryptic peptides contained more
than one PTM. Two such sites involving Asp145/Gln147
and Asp 48/Arg 49 were depicted in Figs. 5 and 6.
Evidence for another such interplay was found for
Met21 and Asp22 (14YLATASTMDHAR25). Significant
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Fig. 2 A major source of degradation of long-lived proteins is racemisation. This spontaneous process affects aspartate, asparagine and serine
residues in unstructured regions of these proteins. Illustrated is the mechanism responsible for Asp and Asn racemization

oxidation of Met21 was detected in all control MBP
samples (Fig. 7a). Since Met can oxidise artifactually
during extraction or digestion [24], and no precautions
were taken specifically to minimize oxidation, this PTM
was initially disregarded. However, other considerations
suggest that Met oxidation in MBP from controls may
be real. Firstly, very little oxidation of Met21 was found
in MBP from MS patients treated in exactly the same
manner. Secondly, in controls, the levels increased as a
function of age. Thirdly, when Met sulfoxide levels were
monitored in the same tryptic peptide where racemization of Asp22 was also present (Fig. 7b), a similar pattern of Met sulfoxide formation was noted. In this case,
as was found with the L-Asp isoform (Fig. 7a), oxidation

of Met 21 increased linearly with age in control MBP
and again minimal oxidation was detected in MS patients. IsoAsp22 levels were consistently higher in this
Met peptide from MS patients (Fig. 7c). Other authors
have described oxidation of Met 21 in MBP with speculation that it may be linked to nearby phosphorylation of
Ser or Thr [22].
MS specific sites of MBP modification

A summary of MBP sites where PTMs differed significantly in controls and MS patients is shown in Fig. 8a.
Mapping of these sites onto a proposed structure of
MBP [3] (Fig. 8b) showed that these sites were clustered
into two distinct regions. Site A incorporated the most

Friedrich et al. Acta Neuropathologica Communications (2016) 4:83
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Fig. 3 Racemization of Asp34 in MBP from controls (●) and multiple
sclerosis (MS) patients suffering from SPMS (○) PPMS (◊) and RRMS
(▽). Conversion of L-Asp34 was measured using the tryptic peptide
HRDTGILDSIGR to (a) HR(D-isoAsp)TGILDSIGR and (b) HR(L-isoAsp)TGILDSIGR. Elevated racemization of Asp34 was detected in multiple
sclerosis patients for both isoforms: HR(L-isoAsp)TGILDSIGR (p < 0.001,
Mann–Whitney-U) and HR(D-isoAsp)TGILDSIGR (p = 0.002, Mann–
Whitney-U). c An example of selected ion chromatographs from
the tryptic digest of MBP from a control (66y) and a multiple
sclerosis patient (48y). The percentage of modification was
determined by the ion intensities of (HRDTGILDSIGR)/(HRDTGILDS
IGR + HRDTGILDSIGR) × 100. Controls, n = 10; multiple sclerosis
patients n = 8

abundant site of racemization in MS patients (Asp34)
with an estimated 32 % of this residue racemized. Site B
contained a dual modification; racemization at Asp48
together with citrulline 49. Asp48 and citrulline 49 were
present in each of the MS patients but were not detected
in controls. This intriguing finding may suggest that
PTMs within two exposed patches of MBP could be
involved in provoking an immune response that ultimately results in MS.

Discussion
This study has revealed the diversity and extent of modifications present in MBP from the normal adult human
brain. In addition, MBP from MS patients displayed
several sites where the covalent alteration differed significantly from that of normal individuals.
Racemization was found to be a widespread PTM of
MBP, with some sites present specifically in MS patients.
In particular racemization of L-Asp to the three other

Fig. 4 Deamidation of Gln147 in MBP from controls (●) and multiple
sclerosis (MS) patients suffering from SPMS (○) PPMS (◊) and RRMS
(▽). Deamidation of Gln147 was measured using the tryptic peptide
GVDAQGTSK (i.e. GVDAQGTSK to GVDAEGTSK). Deamidation was
significantly greater in the multiple sclerosis patients (p < 0.001,
Mann–Whitney-U.). Deamidation increased with age in controls
(R2 = 0.571, p = 0.011)
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Fig. 5 Deamidation of Gln147 coupled with racemization of Asp145
in MBP from controls (●) and multiple sclerosis (MS) patients suffering
from SPMS (○) PPMS (◊) and RRMS (▽). a Conversion of L-Asp145
to the D-isoAsp form in the deamidated peptide (GVDAEGTSK).
Racemization of Asp145 to D-isoAsp GV(D-isoAsp)AEGTSK was
significantly greater in multiple sclerosis patients (p < 0.001,
Mann–Whitney-U). There was no significant difference for the
other Asp isomers; GV(D-Asp)AEGTSK and GV(L-isoAsp)AEGTSK.
The percentage of modification was calculated using the ion
intensities of (GV(D-isoAsp)AEGTSK)/(GVDAEGTSK) × 100. b Selected
ion chromatograph from the tryptic digest of MBP from a control (66y)
and an multiple sclerosis patient (48y). Controls n = 10; multiple
sclerosis patients n = 8

Asp isomers (see Fig. 2) was an abundant modification
and conversion of L-Asp to isoAsp was characterized
at several sites. One particular PTM; isoAsp48 in combination with citrulline 49 was detected only in MS
patients (Fig. 6a).
At other sites, isoAsp was present in MS patients at
levels significantly higher than those of the controls
(Asp34 and Asp82). Although MBP has been investigated for PTMs such as citrullination, phosphorylation,
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Fig. 6 Deimination of Arg49 coupled with racemization of Asp48 in
MBP from controls (●) and multiple sclerosis (MS) patients suffering
from SPMS (○) PPMS (◊) and RRMS (▽). a For the L-Asp version
(FFGGD(Cit)GAPK), no statistically significant difference was found in
the levels of citrulline between controls and multiple sclerosis
patients, but linear regression analysis revealed a significant increase
in the amount of citrulline with age in control samples (R2 = 0.664,
p = 0.004). b Conversion of L-Asp48 to the other Asp isomers in the
tryptic peptide deiminated at Arg49 (FFGGD(Cit)GAPK). An increase
in racemization of Asp48 in the deiminated peptide was seen in
multiple sclerosis patients (p < 0.001, Mann–Whitney-U). Racemization
in this case refers to combined D-Asp, D-isoAsp and L-isoAsp, since the
isomers were not separated under these conditions. The
percentage of modification was determined by the ion intensities of
(FFGGD(Cit)GAPK))/(FFGGD(Cit)GAPK + FFGGD(Cit)GAPK) × 100.
Controls n = 10; multiple sclerosis patients n = 8

methylation and deamidation e.g. [16, 22], age-related
and MS-related changes have not been previously reported. Analysis of human MBP for MS-related modifications in this study, show that it is essential to
evaluate such PTMs in relation to the background of
age-related changes.
Formation of isoAsp at several sites is likely to be
significant in terms of the conversion of MBP to a novel
antigenic form that could potentially act to trigger an
immune response. This is because others have shown

Friedrich et al. Acta Neuropathologica Communications (2016) 4:83
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Fig. 7 Oxidation of Met22 coupled with racemization of Asp23 in
MBP from controls (●) and multiple sclerosis (MS) patients suffering
from SPMS (○) PPMS (◊) and RRMS (▽). a When all Asp versions of
(YLATASTMDHAR) were included, Met oxidation in the controls was
significantly greater than in multiple sclerosis patients (p < 0.001,
Mann–Whitney-U). b Oxidation of Met22 and racemization of Asp23
to isoAsp in YLATASTMDHAR. In the Met-oxidized peptide, racemization
of Asp23 (YLATAST(MetSO)(isoAsp)HAR) was greater in the control
samples (p = 0.008, Mann–Whitney-U). IsoAsp in this case refers to
combined D- and L-isoAsp, since the isomers were not separated
under these conditions. c Racemization of Asp23 to isoAsp(YLAT
ASTM(isoAsp)HAR) in the absence of Met oxidation. Levels of
isoAsp were significantly higher in multiple sclerosis patients
(p < 0.001, Mann–Whitney-U). The percentage of modification was
determined by the ion intensities of (Modified YLATASTMDHAR)/
(YLATASTMDHAR + YLATASTMDHAR) × 100. Controls n = 10;
multiple sclerosis patients n = 8

that replacement of L-Asp by an isoAsp in a peptide
converts it to an immunogen [9, 29]. If, as in the case of
MBP where isoAsp 48 is adjacent to another known
immunogenic amino acid, citrulline (49), then this site
may be particularly antigenic. This dual modification
was detected only in MS patients (Fig. 8). It should however be noted that we cannot definitively conclude that
the MS -specific sites of modification detected in this
study are the cause of MS; their formation may be a
consequence of the disease. This is currently a subject of
further investigations.
The human body contains a number of long-lived
proteins and their degradation may contribute to agerelated diseases [36–38]. Rodent studies using a diet of
labelled amino acids showed that MBP was a stable protein [35]. In the case of human MBP, the amino acid
racemization data alone (Fig. 1) suggest that it, like lens
proteins, is a life-long protein [26]. The protein data
correlate with recent cellular data [43]. For example, the
final number of oligodendrocytes in the human brain is
attained by age ~9 and, once formed, they undergo little
turn over. In addition mature oligodendrocytes myelinate axons very poorly [40]. Thus any turnover of
carbon in myelin that may be associated with an increase in white matter volume [6] appears to involve
changes in lipid, while the myelin proteins are retained.
PTMs such as deamidation and racemization documented for MBP (Fig. 8) are consistent with those expected for susceptible amino acids in proteins that
reside for years in the body. Due to the sheer number of
modifications of different types, the structure of MBP
will inevitably be altered in adult myelin compared with
that when it was first synthesized. For example, deimination alters the net charge on MBP and this will reduce
its binding to the negatively-charged head groups of
phospholipids. This could lead to localized disruption of
myelin [16]. Deamidation, even at just one site, can lead
to significant protein denaturation [12] and racemization
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Fig. 8 (See legend on next page.)
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(See figure on previous page.)
Fig. 8 A summary of the sites of modification detected in human MBP. a A histogram of the percentage modification at particular sites for
controls (■) and multiple sclerosis (MS) patients (□). The underlined residues in bold correspond to the site of modification in MBP. (+) total Asp
racemization in peptide YLATASTMDHAR with and without Met oxidation; (#) total deamidation of Gln147 incorporating all isomers of Asp
GVDAEGTLSK. [^] total Asp145 racemization incorporating the Gln and Glu versions of peptide GVDAEGTLSK. Values for Met sulfoxide 21 were not
plotted since the levels increased significantly with age. All values are the mean of all ages ± SEM. Asterisks represent level of significance
(* p ≤ 0.05, ** ≤ 0.01 and *** ≤ 0.001, Mann–Whitney-U). b A model of MBP23 highlighting the residues that differ significantly in multiple sclerosis.
The amino acid residues in blue correspond to the unmodified conformation, those in magenta illustrate the changes in conformation in
multiple sclerosis. With the exception of TAHYGSLPQK, all the modifications are clustered within two zones as illustrated; site A) contains six and
site B) contains three modified residues. At each of these amino acid residues, the extent of modification was found to be significantly different
in multiple sclerosis patients compared with controls. Sites of Asp racemization labeled as D-Asp in 6b, include all Asp isomers (i.e. D-Asp,
L-isoAsp and D-isoAsp). In the case of TQDENPVVHFFK only the D-isoAsp version was significantly different

of amino acids is also likely to lead to unfolding [17]. In
this study we found a number of sites of racemization.
With regard to the impact of extensive PTMs on
conformation, it should be emphasized that the MBP
structure shown in Fig. 8b is a model [3]. The majority
of MBP is unstructured and this accords with the fact
that PTMs, such as racemization, identified here are
typically localized to unstructured regions [19, 20, 41].
If PTMs of MBP are indeed responsible for inducing
MS, their age-dependent profile can account for an
otherwise puzzling observation i.e. that MS often begins
in the fourth decade of life. It is clear from the graphs
(Figs. 3, 4, 5a, 6 and 7) that by the age of 30, MBP has
undergone a plethora of PTMs. Every amino acid change
effectively introduces a “non-self” motif into the protein;
thus each one, or a combination of several, could potentially generate an immune response. There are precedents
for amino acid racemization, in particular isoAsp formation, eliciting an immune reaction, e.g. autoimmunity to
histone H2B in systemic lupus erythematosus [8, 10].
There is still much to be understood about the detailed
molecular architecture of myelin and questions remain to
be answered in relation to the part played by MBP. In relation to this, if MBP is an intracellular protein, how could
it act as a trigger for an immune response? The literature
is not clear as to whether all of MBP is indeed intracellular. In addition, if indeed all of MBP were originally intracellular e.g. in childhood, it is also possible that changes
that occur with age could lead to partial myelin breakdown and therefore exposure of MBP to the immune
system. Previous research has shown that MBP fragments
can be presented by MHC activating CD8+ cells [44], and
it is well known that in mouse models of MS, demyelination can be induced by injection of MBP fragments [1]. A
number of studies support a role for MBP in the progression of the MS [5, 31, 32].
Since the brains of all people contain MBP that is highly
modified by age 20, it is conceivable that the reason some
people develop MS, while others do not, can be traced
either to the specific types of PTMs and/or the way a
subsequent immune response is modulated. This latter

aspect could involve suppression of the immune system
and components that modulate it, such as vitamin D, or it
might include the masking of altered sites on MBP; for example, chaperones could act to minimize T-cell responses.
In this regard, αB-crystallin expression is increased in MS
lesions [2]. Given that MBP is highly modified by early
adulthood, it will be important in the future to investigate
how such a newly generated ‘non-self‘protein is prevented
from eliciting an antigenic response in controls. It is likely
that other major myelin proteins like proteolipid protein
and myelin oligodendrocyte glycoprotein will be modified
with age, since these are also long-lived [35, 36] and have
also been implicated in MS [14, 15]. Detailed proteomic
analysis of these proteins may therefore yield other potential MS-related epitopes.
Our proteomic data revealed specific sites of modification in MBP that were common to all MS patients. One
conclusion is that these sites may be particularly antigenic.
Other PTM sites have been reported previously [22], e.g.
an increase in methylation of Arg107, deimination of Arg
at several sites, and a reduction of phosphorylation in MS
[22]. The majority of sites of Arg deamination in our study
match those reported previously [22]. Deimination at
some sites was age dependent (Fig. 6a), but in most cases
the amount of citrulline in MBP from MS patients did not
differ significantly from control MBP Sites of racemization
are generated by spontaneous processes which occur more
rapidly in unstructured regions of a protein. For MS
patients to display elevated D-isoAsp in some locations
suggests that MBP may exist in a different conformation
in diseased myelin.
In a recent review [28], Mahad and colleagues considered that MS could be viewed either as a classic autoimmune disease (the so called “outside-in hypothesis”) or
as a disease triggered by a foreign, e.g., viral antigen (the
so called “inside-out hypothesis”). Our observations provide a means to meld these apparently separate mechanisms into one. The formation of MS-specific PTMs of
MBP via spontaneous decomposition mechanisms may
effectively convert an abundant neural protein into a
‘non-self antigen’. The recent report of a lymphatic
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drainage system in the CNS [25] opens up new possibilities of how non-self antigens may be detected by the
immune system.
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5.

6.

Conclusions
The finding herein that specific sites of PTM in MS
patients are localized in two zones of MBP suggests that
these regions may be involved in antigen recognition by
the body’s immune surveillance machinery. This discovery unlocks the possibility of selectively masking such
sites on MBP using small molecules. If this hypothesis
can be verified, it may lead to the development of a new
class of drugs that could potentially inhibit the onset of
MS, as well as help in modulating the immune response
of patients who already have developed the disease.
Additional file
Additional file 1: Sites of Asp, Asn, Ser and Gln deamidation / racemisation.
In addition to the sites of modification described, other sites of modification
were detected in MBP. Some differences between MS patients and controls
for Asp, Asn, Ser and Gln are summarised. (DOCX 1.84 mb)
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